Anguita Sánchez M
Servicio de Cardiología, Hospital Reina Sofía, Córdoba.
Rev Esp Cardiol. 1995 Nov;48(11):699-709.
During the last years, our knowledge on the pathophysiology and therapy of congestive heart failure has experienced a great growth. The goals of the therapy for heart failure have changed since new drugs have demonstrated to increase survival as well as to improve symptoms and functional capacity in patients with this syndrome. It has also been shown that therapeutic intervention can prevent the development of heart failure and decrease long-term mortality in patients with asymptomatic left ventricular dysfunction. In this article, we have reviewed the results from the most important clinical trials carried out during the last years in patients with overt congestive heart failure and asymptomatic left ventricular dysfunction with several drugs (digitalis, diuretics, angiotension-converting-enzyme inhibitors, other vasodilators, calcium-antagonists, non-glycoside inotropics antiarrhythmics, etc.). Nevertheless, in spite of this impressive increase in the knowledge on heart failure, some important questions remain unanswered.
在过去几年里,我们对充血性心力衰竭的病理生理学和治疗方法的认识有了很大的进展。由于新药已被证明能提高心力衰竭患者的生存率,并改善其症状和功能能力,心力衰竭的治疗目标已经发生了变化。研究还表明,治疗性干预可以预防心力衰竭的发生,并降低无症状左心室功能不全患者的长期死亡率。在本文中,我们回顾了过去几年针对明显充血性心力衰竭患者和无症状左心室功能不全患者使用几种药物(洋地黄、利尿剂、血管紧张素转换酶抑制剂、其他血管扩张剂、钙拮抗剂、非糖苷类正性肌力抗心律失常药等)进行的最重要临床试验的结果。然而,尽管我们对心力衰竭的认识有了显著提高,但一些重要问题仍未得到解答。